Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-880 and VX-017 in Type 1 Diabetes with Impaired Hypoglycemic Awareness
NCT04786262Phase 3Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Dec 2027
- Modality
- Beta Cells, Stem Cell Therapies
- Countries
- 10
01
Overview
A Phase 3 trial of zimislecel, VX-017 in type 1 diabetes mellitus (T1D), sponsored by Vertex Pharmaceuticals. Started Mar 2021; status: recruiting.
02
Drugs
zimislecelVX-017
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04786262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04786262.